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The tripeptidyl-peptidase II complex consists of repeated 138kDa subunits, assembled into two twisted strands that form a
high molecular weight complex (>5MDa). TPPII, like many other cytosolic peptidases, plays a role in the ubiquitin-proteasome
pathway downstream of the proteasome as well as in the production and destruction of MHC class I antigens and degradation
of neuropeptides. Tripeptidyl-peptidase II activity is increased in cells with an increased demand for protein degradation, but
whether degradation of cytosolic peptides is the only cell biological role for TPPII has remained unclear. Recent data indicated that
TPPII translocates into the nucleus to control DNA damage responses in malignant cells, supporting that cytosolic “housekeeping
peptidases”mayhaveadditionalrolesincellbiology,besidestheircontributiontoproteinturnover.Overall,TPPIIhasanemerging
importance in several cancer-related ﬁelds, such as metabolism, cell death control, and control of genome integrity; roles that are
not understood in detail. The present paper reviews the cell biology of TPPII and discusses distinct roles for TPPII in the nucleus
and cytosol.
1.Introduction
Tripeptidyl-peptidase II (TPPII), discovered in 1983, is an
aminopeptidase that removes tripeptides from the free N-
terminus of oligopeptides and is regarded as a housekeeping
enzyme of eukaryotic cells [1–3]. TPPII is present in all
examined higher species, including invertebrates (e.g., C.
Elegans and D. Melanogaster), is absent in certain protozoa
and many fungal species, but a TPPII orthologue is also
present in S. Pombe [4, 5]. It is the largest cytosolic peptidase
complex of mammalian cells (>5MDa), and is composed
of two twisted strands of stacked TPPII dimers, composed
of unique 138-kDa subunits [6]. The N-terminal domain
of TPPII contains a serine peptidase site, with a classical
catalytictriadofserinepeptidases(Ser-449-His-264-Asp-44)
[7]. The only demonstrated method of activation of this
enzyme is through complex formation, which could be the
principal means by which the enzymatic activity of TPPII is
regulated [8–10]. TPPII is known to participate in protein
turnover, presumably in concert with the proteasome and
other exopeptidases [11–14], and possesses the ability to
degrade oligopeptides >15 amino acids long [15]. It cleaves
eﬃciently after hydrophobic residues, fails to cleave before or
after proline residues, and displays endopeptidase activity by
cleaving after lysine residues, although this activity is weak
when compared to its exopeptidase function [3, 12].
Proteindegradationiscriticalformanycellularfunctions
and alterations in the metabolism of proteins involved in
the cell cycle and apoptosis may result in uncontrolled cell
division, which can lead then to malignant transformation.
The overexpression of TPPII observed in a speciﬁc tumor
as Burkitt’s lymphoma [14], where an impaired proteasome
function is also present, points out the essential role that
this peptidase may play in tumor metabolism. TPPII may
increase the rate by which free amino acids are produced
during protein breakdown, a role shared with many other
cytosolic and nuclear peptidases. Also, like other cytosolic
peptidases, TPPII inﬂuences MHC class I processing; usually
through N-terminal trimming or destruction of MHC class
I epitopes [15–21]. Degradation of peptide hormones is2 Journal of Oncology
another common theme, for example, for TPPII, Thimet
oligopeptidase (TOP), and Dipeptidyl-peptidase-4 (DPP-4)
[2, 22, 23]. TPPII degrades CCK-8, an octapeptide that is the
main form of CCK in mammalian brain [2, 24].
So, is the cell biological role of TPPII restricted to protein
turnover and degradation of cytosolic peptides, or does this
very large peptidase complex also have other types of more
specialized functions? A regulatory role has previously been
reported for DPP-4, a ubiquitously expressed transmem-
brane glycoprotein with known substrates that include sev-
eral growth factors, neuropeptides, and chemokines. DPP-
4 belongs to the S28 Serine protease family, and inhibitors
of this peptidase are now in clinical practice for treatment
of type 2 diabetes [23]. The expression and localization of
TPPII is altered in response to several forms of stress, which
suggested a possible role for TPPII in signaling. In several
cases, remarkable phenotypes are observed upon altered
expression of TPPII, in animals or cell lines; phenotypes of
unclear causes (Table 1)[ 25, 34, 36, 37, 42, 48]. Herein, we
review some of the main reported aspects of TPPII biology
in housekeeping versus signaling in response to cellular
stress.
2. TPPIIas a Generatorof MHCClass
I-BindingPeptides
Most investigations of TPPII in protein turnover have
focused on its role in the generation of MHC class I-
bound peptides, a common way to probe the speciﬁcity
of cytosolic proteolysis. Peptides bound to MHC class
I molecules are derived from the pool of peptides that
originate from degraded cytosolic proteins, which are made
available for assembly with MHC class I through TAP1/2-
mediated translocation across the ER-membrane (Figure 1).
Although proteasomes are essential in the generation of
the C terminus of most peptides that bind MHC class I
molecules, proteasomal inhibitors have a negligible eﬀect
on a subset of MHC class I epitopes. In particular, the
generation ofepitopes with alysine residue asthe C-terminal
anchor is scarcely altered by proteasome inhibition (epitopes
of HLA-A3, -A11, and -B35) [52]. During the ongoing
search for additional peptidase activities in the generation of
MHC class I-bound peptides several epitopes generated by
TPPII have been indicated, for example, HIV-1 Nef 73-82;
an immunodominant HLA-A3/A11 epitope (Table 2)[ 16].
However, this is not exclusive to lysine anchor motifs, as
recently observed in two HLA-A2-restricted EBV-derived
epitopes of LMP1 (Table 2)[ 19], and the H-2Kd-restricted
Inﬂuenza virus epitope NP147-155, although another report
failed to conﬁrm the latter ﬁnding [20, 49] .Ad e p e n d e n c eo n
TPPII in the presence of proteasomal inhibition was found
for the L. monocytogenes-derived CD8+ T cell H-2Kd epitope
LLO91-99 whereas another epitope (p60 449-457) required
the activity of both TPPII and the proteasome in infected
macrophages [21]. Moreover, two further Listeria epitopes
were found to be unaﬀected by TPPII inhibition (p60-217-
225, p60-476-484) [21]. Studies using extended versions of
peptide epitopes have revealed that TPPII can contribute to
Table 1: Phenotypes/pathways inﬂuenced by altered expression of
selected cytosolic peptidases&.
Pathway/phenomena# Model Ref.
Tripeptidyl-peptidase II (TPPII)
Neuropeptide degradation cells [2]
MHC class I processing∗ cells [15–21, 25–28]
KO/GTmice [18, 27]
Muscle wasting/cachexia rats [29, 30]
Resistance to proteasome inh.∗ cells [11–14, 31]
Apoptosis progression∗ cells [25]
DNA damage response∗ cells [32, 33]
G2/M progression cells [34, 35]
Fat formation KO (+/−)m i c e [ 36]
Hematopoietic homeostasis∗ KO/GT mice [27, 37]
Organismal lifespan KO mice [37]
Thimet Oligopeptidase (TOP)
Neuropeptide degradation cells [22]
APP processing cells [38]
MHC class I processing cells [39]
Bleomycin Hydrolase
APP processing cells [40]
MHC class I processing∗ cells [41]
Bleomycin resistance KO mice [42]
Dermal maturation KO mice [42]
Astrogliosis KO mice [43]
Cognitive functions KO mice [43]
Homocysteine metabolism cells [44]
Puromycin-sensitive aminopeptidase
(PSA)
MHC class I processing∗ cells/KO mice [45]
G2/M progression cells [46]
Growth, reproduction KO/GT mice [47]
Anxiety, pain control GT mice [47]
&Phenotypes and pathways studied in live mammalian cells or in mice.
#Both known pathways and phenomena, several of unknown cause, are
included in this list. Thereby, it is possible that some phenomena are the
result of some of the known pathways, although the link has not been made.
For example, it is unclear whether degradation of neuropeptidescontributes
to any of the signs in TPPII−/− mice.
∗The contribution of the peptidase is debated, since reports show both a
presence and absence of a role in the phenomenon.
@K O :k n o c k - o u tm i c e ;G Tg e n e - t r a p p e dm i c e .
APP: amyloid precursor protein.
trimming of their N-terminals, as shown for the H-2Kb-
restricted ovalbumin epitope SIINFEKL and RU-1, a renal
carcinoma tumour antigen [50, 51]. Nevertheless, presenta-
tion of SIINFEKL from intact OVA protein was only mod-
estly reduced by inhibition of TPPII expression [51]. Fur-
thermore, pharmacological TPPII inhibition failed to inhibit
the processing of six diﬀerent lymphocytic choriomeningitis
virus- (LCMV-) derived T cell epitopes, although a small
enhancement of antigen processing was noted in some cases
[26]. Similar results were found for SIINFEKL and an H-
2Ld-restricted murine cytomegalovirus (MCMV) epitope
(pp89/168-176) [26]. Moreover, experiments using dendriticJournal of Oncology 3
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Figure 1: The eucaryotic circuit of protein turnover—recycling of proteins into amino acid building blocks. Amino acids are incorporated
into proteins that are subsequently degraded by the ubiquitin-proteasome pathway into peptides, of which a small minority are sampled
by the MHC class I processing pathway, in vertebrates. Downstream of proteasomal protein degradation, most peptides are degraded into
shorter peptides and amino acids by cytosolic peptidases, a step function that is highly redundant due to the presence of many diﬀerent
cytosolic peptidases. Note that a few cytosolic peptides are not proteasomal degradation products, but peptide hormones. ∗∗Examples
of cytosolic peptidases: Tripeptidyl-peptidase II (TPPII), Bleomycin Hydrolase (BLMH), Thimet oligopeptidase (TOP), and Puromycin-
sensitiveaminopeptidase(PSA);seealso Table 1 wherephenotypes induced bytheir modulationincells andknockoutanimals aredisplayed.
Theproteasomeispresentinalleucaryotes(aswellasinarchaebacteria);severaloligopeptidasesalsoshowahighlevelofconservation.TPPII
orthologues is expressed in D. Melanogaster, C. Elegans, A. Thaliana;a sw e l la si nS. Pombe.
cells (DCs) from TPPII−/− knockout mice revealed normal
presentation of several LCMV epitopes (GP33-41, GP276-
286, NP396-404), and the ovalbumin epitope SIINFEKL
was generated even more eﬃciently by TPPII−/− dendritic
cells (DCs) than by their control counterparts [18]. In
addition,usingTPPIIgene-trappedmice,alackofsigniﬁcant
diﬀerence compared to control mice (TPPII wild type) was
seen in the response to four epitopes from LCMV (Table 2;
>90% reduction in TPPII expression) [27]. The presentation
of peptide precursors with long N-terminal extensions in
TPPII gene-trapped embryonic ﬁbroblasts was modestly
reduced in vitro whereas the presentation of full-length
OVA protein was unaltered. Further, an equivalent CD8+ T
cell response was induced in vivo in wild type and TPPII-
deﬁcient mice immunized with recombinant lentiviral or
vacciniavectorsregardlessoftheextensionattheN-terminus
of SIINFEKL [27]. Thus, only a minority of examined MHC
class I epitopes depend on TPPII for their generation.
Does TPPII inﬂuence the overall rate of production of
MHC class I ligands? Such a role has been suggested by
experiments using a speciﬁc TPPII inhibitor to block the
cell surface expression of MHC class I almost as eﬃciently
as a proteasomal inhibitor [15]. However, using both RNA
interference and pharmacological inhibition by butabindide,
Marcillaetal.obtainednoeﬀectonpeptideloadingforHLA-
B27, -A3, -A68, and B14-expressing cells [53]. Furthermore,
York et al. demonstrated that elimination of TPPII from
human cells using RNAi does not decrease the overall supply
of peptides to MHC class I molecules [51]. In addition the
surface expression of MHC class I molecules (H-2Kb,D b)4 Journal of Oncology
Table 2: Reported TPPII-dependency in processing of MHC class I-bound epitopes in live cells.
Source MHC class I Sequence Cell type In vivoΨ Ref.#Θ
Requirement for TPPII∗
HIV-1 Nef73−82 HLA-A3/A11 QVPLRPMTYK&@ DC, LCLs — [16]
EBV-LMP1 HLA-A2 YLLEMLRWL&@ COS cells, LCLs — [19]
EBV-LMP1 HLA-A2 YLQQNWWTL&@ COS cells, LCLs — [19]
Inﬂuenza NP147−155 H-2K
d (TYQRTRALV)&@# HEK-293, L cells — [20, 49]#
Listeria-LLO91−99 H-2K
d GYKDGNEYI
&Δ J774, BMM — [21]
Listeria-p60449−457 H-2K
d IYVGNGQMI& J774, BMM — [21]
RU134−42 HLA-B51 VPYGSFKHV& BB-64 Renal carcinoma — [50] Θ
No requirement for TPPII
Listeria-p60217−225 H-2K
d KYGVSVQDI& BMM — [21]
Listeria-p60476−484 H-2K
d KYLVGFGRV& BMM — [21]
OVA H-2K
b SIINFEKL&§ BMC-2, TPPII−/− DC TPPII−/− GT
 [18, 26, 27, 51]
LCMV NP118−126 H-2L
d RPQASGVYM& J774 — [26]
LCMV GP33−41 H-2K
b/D
b KAVYNFATC&§ BMC-2, HEK-293, TPPII−/− DC TPPII−/−,G T [ 18, 26, 27]
LCMV GP276−286 H-2D
b SGVENPGGYCL&§ BMC-2, HEK-293, TPPII−/− DC TPPII−/−,G T [ 18, 26, 27]
LCMV NP396−404 H-2D
b FQPQNGQFI&§ BMC-2, HEK-293, TPPII−/− DC TPPII−/−,G T [ 18, 26, 27]
LCMV NP205−212 H-2K
b YTVKYPNL&§ BMC-2 GT [26, 27]
LCMV GP92−101 H-2D
b CSANNSHHYI& BMC-2, HEK-293 — [26]
MCMV- pp89168−176 H-2L
d YPHFMPTNL& Lc e l l s — [ 26]
Epitope destruction by TPPII
Survivin HLA-A2 ELTLGEFLKL& Colon carcinoma — [28]Θ
∗The eﬀect considered has to be at least partial in the processing of an epitope in live cells.
ΨInv i v odependence on TPPII for generation of a CTL response against epitope, the column contains the animal used.
#The requirement for TPPII in the processing of this epitope is debated.
ΘEvidence in some reports is based only on AAF-CMK, an inhibitor that is however not TPPII-speciﬁc.
Evidence base: catalytic inhibitor—&; siRNA—@; gene-deﬁcient cells—§.
GT: Gene-trapped TPPII-deﬁcient mouse.
ΔOnly in the presence of proteasomal inhibitor.
Cells: Dendritic cells, COS: Chinese Hamster Ovary cells, LCL: Lymphoblastoid cells, HEK293: Human embryonic kidney cells, BMC-2 and J-774 -
macrophage cell lines, BMM: Bone-marrow macrophages.
o ns e v e r a lc e l lt y p e sf r o mT P P I I −/− gene-deﬁcient mice as
well as TPPII gene-trapped mice was even slightly increased,
indicating a modest destructive role in MHC class I antigen
production [18, 27]. A potential role for TPPII-mediated
destruction of a speciﬁc MHC class I epitope has also been
observed in colon carcinoma cells, when presentation of an
HLA-A2-restricted epitope of survivin was examined [28].
In conclusion, studies have demonstrated a contribution
of TPPII in the processing of selected antigens, but its
overall importance in the generation of MHC class I-bound
peptide pools appears to be minor [54]. TPPII inﬂuences
production of MHC class I ligands; (1) downstream of
the 26S proteasome, in its main nonredundant role, by N-
terminaltrimming oflonger(>15a.a.)peptideintermediates
generated by the proteasome. However, this role may have
limited importance for the MHC class I pathway in live cells,
since the majority of peptides that the proteasome produces
are shorter than this [51]. TPPII can also act; (2) in the
direct generation of a minority of MHC class I epitopes, for
example, those with basic C-termini, although the number
of known epitopes generated by TPPII independently of the
proteasome is very small (Table 2). No cytosolic peptidase of
major importance for trimming of MHC class I antigens has
yet been elucidated, instead most peptides appear to be N-
terminally trimmed by ER aminopeptidase 1 (ERAP1) [55–
57]. The main inﬂuence of TPPII on MHC class I processing
is likely to be cytosolic destruction of epitopes, since data
from two diﬀerent types of TPPII-deﬁcient mice show
increased MHC class I expression [18, 27]. A destructive
inﬂuence on MHC class I antigen processing has also been
reported for Puromycin-sensitive aminopeptidase (PSA) and
Thimet Oligopeptidase (TOP) [39, 45]. Sequencing of the
MHC class I-bound repertoire in TPPII−/− cells may reveal
more about subsets of MHC class I antigens that are
negatively or positively inﬂuenced by TPPII expression.
3. TPPIIinContributiontoProteinMetabolism
Themainhousekeeping roleofcytosolic peptidases istopro-
vide suﬃcient free amino acids for cellular needs in protein
synthesis. Several studies have addressed the expression of
TPPIIinsituationsofincreaseddemandforaminoacids,that
is, focusing on the absolute levels of TPPII expression and/or
activity rather than its cleavage speciﬁcity in sampling of
MHC class I antigens. Conditions of increased proteasomal
protein degradation and demand for amino acids dueJournal of Oncology 5
to tumor-induced cachexia in rats was found to cause
enhanced activity of TPPII in muscles [29]. Furthermore,
a glucocorticoid-dependent muscle wasting correlates with
high TPPII activity during sepsis [30]. In addition, increased
expression of TPPII has been observed in EL-4 lymphoma
cells grown in cell culture medium diluted with PBS [25].
In these studies, the increased expression of TPPII correlated
with an increased demand for the amino acid production
by the ubiquitin-proteasome pathway (UPP), due to either
increased external demand or decreased supply of amino
acids in the medium. Given that the UPP recycles protein
building blocks into free amino acids, the question of how
TPPII responds to a decrease in proteasomal activity may
be raised [58]. Such experiments have been performed, by
adapting invitro cell lines to the presence of covalentlyacting
proteasomal inhibitors (NLVS, ZL3VS, or Lactacystin). Such
adapted cells displayed inhibited activity of the proteasome
and upregulation of TPPII [11, 12, 49]. In addition, a
similar phenotype (low proteasomal activity and high TPPII
a c t i vi ty )w a sp r e s e n ti nm o s tB u r k i t t ’ sl ym p h o m ac e l l s( B L s ) ;
where the oncogene c-Myc was strongly upregulated [14].
The c-Myc protein is stabilized in a number of BL cell lines,
suggesting that defective UPS c-Myc proteolysis may play a
role in the lymphomagenesis. It should however be noted
that TPPII is not upregulated in several types malignant
cells adapted to the presence of Bortezomib (a boronic acid
proteasome inhibitor) [31]. Nonetheless, these ﬁndings are
consistent with TPPII as a housekeeping enzyme in protein
turnover with upregulation either during increased amino
acid demand or in response to inhibited endogenous supply
by the UPP (Figure 2(a)).
In addition to the role of TPPII in oligopeptide degrada-
tion downstream of the proteasome, the ﬁnding of increased
TPPII activity in combination with blocked chymotryptic
proteasomal activity in NLVS-adapted EL-4 cells (EL-4ad,
growing in either NLVS or lactacystin) initiated a discussion
as to whether TPPII could contribute to protein turnover in
the absence of the proteasome [11, 12]. This theory was lent
further weight by that stable overexpression of TPPII in an
EL-4 transfectant allowed resistance to NLVS-treatment, as
wellastheﬁndingofreducedproteasomalactivityinBLs[13,
14]. However, it should be mentioned that EL-4ad, BLs and
EL-4.pcDNA3-TPPII cells (over-expressing TPPII) still had
some proteasomal activity, and that they were probably still
dependent on this activity [14, 15, 59]. Present data support
a housekeeping role for TPPII mainly downstream of the
proteasomal protein degradation, and a TPPII-mediated
degradation of protein substrates has thus far not been
demonstrated. Nonetheless, a TPPII-mediated contribution
toproteinturnoverinparallelwiththeproteasomecannotbe
excluded, for example, through the degradation of unfolded
polypeptides.
4. TPPIIinApoptosis Regulation
andGeneticStability
In addition to a housekeeping function in protein turnover,
with the consequent generation of MHC class I ligands,
several reports have indicated other more specialized roles
for TPPII. The enigma discussed herein is common to many
other cytosolic peptidases, characterized by being unclear;
their physiological roles and the peculiar phenotypes seen
in cell lines and mice upon modulation of their expression
(Table 1)[ 25, 34, 36, 37, 42, 48]. An altered expression of
peptide hormones may have a role in the phenotypes of
peptidase knockout animals, but is less likely to aﬀect cell
lines in vitro. Another mechanism for such observations
may be an altered intracellular concentration of short
peptides that modulate protein-protein interactions, that
is, an indirect consequence of the contribution to protein
turnover [46, 60]. Alternatively, they may have direct roles
in signaling, by targeting a pool of natural substrates (as
reported for DPP-4, in cleavage of substrates at the cell
membrane [23]).
Inhibited apoptosis-sensitivity of EL-4ad cells correlated
with increased expression of antiapoptotic proteins (IAPs),
whose translation are turned on during stress through IRES
(internal ribosomal entry site) sequences in their mRNAs
[25, 58]. IAPs are endogenous inhibitors of caspases that are
degraded by the proteasome in response to cytochrome C
release (by their internal RING-domain, i.e., a mechanism of
autoubiquitination)[61].IAPscausedresistancetoapoptosis
in EL-4ad cells, and increased IAP expression was also
present in transfected cell lines with stable overexpression of
TPPII [25, 34]. This overexpression of IAP was connected
to a compromised proteasomal activity, in presence of
an overexpression of TPPII, which anyway was unable
itself to degrade this class of proteins. Stabilization of
IAPs may point to the hyphotesis that TPPII contributes
to tumorigenicity by sustaining protein turnover without
inﬂuencing degradation of antiapoptotic and proliferative
proteins [25] .T h ee x p r e s s i o no fI A P sw a sv a r i a b l eb e t w e e n
TPPII-transfected cell lines, with high expression of XIAP
and cIAP1 in EL-4.pcDNA3-TPPII whereas HEK-293-TPPII
cells expressed mainly high levels of c-IAP2. Furthermore,
overexpression of TPPII by transfection into several cell lines
causes evasion of mitotic arrest, as well as the formation
of polyploid cells, possibly through abnormal centrosome
regulation [34, 35]. Interestingly, the ectopic expression of
cIAP1 perturbs mitotic control and promotes the formation
of polyploid cells [62]. Previous ﬁndings in the patent
literature support this evidence, showing that overexpression
of TPPII in tumor cells creates genetic instability by causing
centrosomal duplication errors [63]. In addition, in a study
where WT and TPPII deﬁcient ﬁbroblasts were used NF-
κB activation upon TNF addition was defective in TPPII-
deﬁcient ﬁbroblasts, as seen by the reduced nuclear accu-
mulation of NF-κBp 6 5[ 37]. Constitutive activation of the
NF-κB pathway is involved in diﬀerent forms of cancer such
as leukemia, lymphoma, colon cancer, and ovarian cancer.
Further, previous data indicated that also PSA is associated
with the mitotic apparatus and is involved in mitotic control
[64]. Thus, TPPII expression has a substantial impact on
IAP expression, programmed cell death and mitotic errors,
but how TPPII controls these phenotypes still remains to be
elucidated.6 Journal of Oncology
5. Nuclear Translocation of TPPII in
Response to ROS andDNA Damage
Recent reports have studied the localization of TPPII in
response to γ-irradiation, one demonstrated a translocation
of TPPII into the nucleus [33], while the other authors did
not observe this ﬁnding [65]. In the former study [33],
TPPII accumulated in the nucleus in 7 out of 9 γ-irradiated
tumor cell lines, and also in response to treatment with
etoposide. This event was dependent on the presence of
reactive oxygen species (ROSs) produced by mitochondria,
since nuclear expression of TPPII was blocked by N-acetyl-
cystein (an anti-oxidant) as well as rotenone (an inhibitor
of mitochondrial respiration) [33]. Most cellular ROS are
producedbythemitochondria,andROSrepresentaconstant
hazard for the cell, most notably to the genome [66].
Such ROS have a strong inﬂuence on the DNA damage
response; for example, in p53 expression in response to γ-
irradiation of leukaemic cells [67, 68]. The other authors,
[65] used both immunoﬂuorescence and cytosolic/nuclear
fractionation to investigate the localization of TPPII but
nucleartranslocationwasnotdetectedinEL4,COScells,and
transformed ﬁbroblasts after diﬀerent doses of γ-irradiation.
An aﬃnity-puriﬁed rabbit serum against a synthetic peptide
corresponding to the NH2 terminus of TPPII was used
for western and immunocitochemistry analysis. ROS levels,
and the requirement for high cell densities, in experiments
studying nuclear TPPII localization, may be the most likely
reason for the observed experimental discrepancies [33, 65].
A role for TPPII in the nuclear expression of p53
in response to DNA damage was suggested, but this is
currently controversial. Nuclear TPPII expression correlated
with p53 expression in lymphoma cells [33]; for example,
a short peptide-derived inhibitor that inhibited nuclear
accumulation of TPPII also inhibited nuclear expression of
p53 [33]. However, c-myc transformed ﬁbroblasts, as well
as normal cells, from gene-deﬁcient TPPII−/− mice have
normal p53 protein levels and functional p53 signaling [65,
69]. These diﬀerences may depend upon the role played by
TPPII in diﬀerent malignant cell types, but the potential
role for p53 in the DNA damage is at this point uncertain.
A putative role for TPPII in nuclear regulation of DNA
damage responses is illustrated in Figure 2(b), alongside the
housekeeping role for TPPII in Figure 2(a). Proteins with
roles in DNA damage responses, that control cell cycle arrest
and DNA repair, have attracted great interest as putative
targets in cancer treatment as sensitizers to classical cancer
therapy, such as γ-irradiation. In this respect, modulation of
TPPII function may be interesting in cancer therapy [33, 65].
Several previously studied housekeeping proteins were
found to acquire additional roles in response to stress.
Mitochondrial respiration is linked to DNA damage
responses through the dislocation of cytochrome C from
their inter-membrane space into the cytosol, the classical
trigger of caspase 9-activation and apoptosis. Furthermore,
nuclear release of linker histone H1.2, into the cytosol has
been reported as essential for mitochondrial cytochrome
C release [70]. Thus, in addition to its housekeeping role
in control of chromatin topology, H1.2 is also a signaling
protein in γ-irradiated cells. Another housekeeping protein
translocates in the reverse direction; apoptosis-inducing
factor (AIF), a ﬂavoprotein important for mitochondrial
function, is shifted from the mitochondrial intermembrane
space to the nucleus, where it promotes caspase-independent
apoptosis[44].Thedualrolesofthesehousekeepingproteins
may reﬂect the necessity to disrupt basal metabolism in
response to hostile conditions.
6. Observations inTPPII-Deﬁcient Animals
TPPII is present in the genome of most studied eukaryotes,
although it is absent from certain species of protozoa and
fungi [4]. Suppressed expression of TPPII orthologues in C.
Elegans (siRNA) [36], A. Thaliana (T-DNA mutant) [71],
and S. Pombe (gene deletion) [4]h a dn oo b v i o u se ﬀects on
viability. Three investigations into TPPII-deﬁcient mice have
recently been carried out; knock-out mice homozygotic for
TPPII−/− [37], gene-trapped mouse that failed to produce
TPPII homozygous mutants due to early embryonic lethality
(before day 9,5) [36], and one study of a homozygously
mutant TPPII gene-trapped animal with >90% reduced
expression of TPPII [27]. In TPPII−/− mice declining
levels of thymocytes and peripheral CD8+ cells was present
in mice >12 months of age. Further, TPPII−/− displayed
splenomegaly, increased granulocyte numbers in the spleen
and extramedullary hematopoiesis [37]. In addition, deregu-
lation of NF-κB activation and premature senescence were
seen in TPPII−/− ﬁbroblasts cultured in vitro.S e n e s c e n c e
may be regarded as a response to chronic DNA damage,
which is interesting when considering TPPII in relation to
DNA damage responses [72]. An alternative explanation for
suchsenescencecouldbefailuretoactivateNF-κBinassocia-
tion with TPPII deﬁciency, as observed in TPPII−/− ﬁbrob-
lasts, since altered NF-κB activation has repeatedly been
observed alongside cellular senescence and systemic aging
[73]. In the study by McKay et al., which failed to result in
gene-trapped TPPII-mutant homozygotes, a phenotype was
observed for TPPII-mutant heterozygotes, as demonstrated
by decreased fat cell formation [36]. This study indicated
an evolutionarily conserved role for TPPII, since C. elegans
with downregulated TPPII expression also showed reduced
fat storage, but this eﬀect is unrelated to expression of the N-
terminal region of TPPII, containing its peptidase site. The
study of gene-trapped homozygously TPPII-mutant mice,
produced by Kawahara et al., showed a reduction of TPPII
mRNA expression of >90%, resulting in apparently healthy
animals [27]. In these TPPII-deﬁcient mice, there was an
absence of observations made in TPPII−/− knockout mice,
bothwithrespecttohematopoieticsymptoms,andabnormal
histology [27]. From reviewing the literature it is clear that
mutating the TPPII gene, causing a reduced expression,
results in diverse eﬀects. It is not clear why there is such
majordiﬀerenceinthevariousTPPIImutantmiceproduced,
and whether the diﬀerence in observed phenotypes among
TPPII-deﬁcient mice depend on animal housing or other
parameters. It should be pointed out that TPPII-mutant
mice produced by gene-trap may have incomplete inhibition
of TPPII expression, or other eﬀects of the genetic insert;Journal of Oncology 7
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Figure 2: Distinct functions for TPPII in the nucleus and cytosol. (a) TPPII contributes to protein turnover in concert with components
of the ubiquitin-proteasome pathway and other cytosolic peptidases. The expression and activity of TPPII is inﬂuenced by the following.
(1) The cellular recycling of amino acids from protein building blocks, that is, through degradation of proteins by the ubiquitin-proteasome
pathway, inhibited recycling leads to increased activity of TPPII [11, 12, 14]. (2) The external supply of amino acids. Dilution of cell culture
medium in PBS increases TPPII levels [25]. (3) The organismal demand for amino acids. An increased demand, as observed in cachexia also
increases TPPII activity [29, 30]. (4) Endogenous demand for amino acids; a factor that potentially increases TPPII; remains to be tested. (b)
In response to ROS production and DNA damage, TPPII shifts its localization from cytosolic to nuclear. This may contribute to the DNA
damage response and apoptosis triggering, a model that is under debate. The cytosolic-nuclear shift of TPPII may create a link between
mitochondrial respiration and DNA damage signaling in the nucleus.8 Journal of Oncology
compared to mice produced by homologous recombination.
In conclusion, all reports of MHC class I processing in
TPPII-mutant mice indicated a minor role for this peptidase
in the production of MHC class I antigens (discussed in
the previous section). Further, there are observations on
aberrant cells death control within the hematopoietic system
(that diﬀer between gene-trapped and knock-out animals),
and a further discussion must await more data from these
animals [27, 36, 37].
7. Conclusion
In this paper, we have reviewed the cell biology of TPPII,
and discussed distinct housekeeping versus stress-induced
functions of TPPII. This discussion may in part be appli-
cable to other evolutionary conserved peptidases that also
have largely unknown cell biological roles. One example
is Bleomycin hydrolase (the mammalian homologue of
yeast Gal6), a peptidase complex (6 × 40kDa), which is
upregulated in some cancer cells and with an ability to bind
double- and single-stranded DNA [42]. The link between
TPPII and responses to stress, in particular to DNA damage,
may be of considerable interest in cancer biology.
TPPII is upregulated during conditions of both external
and internal depletion of amino acids, as observed from
starvation or inhibited recycling by UPP inhibition, as well
as increased organismal demand for amino acids observed
in cachexia. The role for TPPII in processing of MHC class
I antigens appears limited (at least compared to that of the
proteasome), and more devoted to destruction than genera-
tion of epitopes, as also observed for TOP and PSA [39, 45].
Further, TPPII degrades CCK; in line with the observed
degradation of peptide hormones by DPP-4 and TOP [2, 22,
23]. In intracellular signaling, the perturbation of apoptosis
control and genetic stability mediated by the overexpression
of TPPII may be due to increased IAP expression, but other
regulatory alterations caused by TPPII are not excluded. The
cytosolic-nuclear translocation of TPPII into the nucleus in
several types of malignant cells exposed to genotoxic stress
has indicated a link to DNA damage responses (Figure 2(b)).
Speciﬁc substrates or interaction partners of TPPII may
yield a deeper insight into how this evolutionary conserved
peptidase complex contributes to intracellular signaling.
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